Jen Eisenberg attended the University of Michigan and received a degree in linguistics and Spanish.
This story has been updated to show that the core PPI figure of ex-food, energy and trade services fell 0.1 percent in May.
This story has been updated to reflect that CarMax and KBHome report earnings Friday, June 19, not Friday, June 12.
This story has been updated to reflect that Wingstop rose nearly 61 percent in its debut.
David Cancel is the former chief product officer at HubSpot.
This story has been updated to show the correct web address is PleaseProtectConsumers.org.
Correction: This story has been updated to reflect that Chip Wilson and his family have not yet sold their Lululemon stock.
Twitter CFO Anthony Noto is overseeing marketing at the company but is not assuming the role of chief marketing officer.
An earlier version of this story, which included information contained in a report by Avalere Health, incorrectly stated that the drug Kalydeco had not yet been launched for sale. In fact, Kalydeco went on sale in 2012. The new indication for cystic fibrosis that Avalere was highlighting in its report uses Kalydeco in combination with another drug, lumacaftor, and will be marketed under the name Orkambi. At the time that Avalere did its analysis and completed the first draft of the paper, the new name for this combination was not yet announced. The drug's manufacturer, Vertex Pharmaceuticals, said an FDA decision on whether to approve Orkambi is expected in July, and if it is approved the company plans to launch the drug immediately thereafter, not in 2016. Avalere said that its overall cost projections in the report are not affected.
This version corrected Merkel's quote to "international law."